Annie-Claude Benichou, speaking at World Orphan Drug Congress 2011

Annie-Claude Benichou,
CMO
Alaxia

Dr. Benichou has 18 years of experience in the management of clinical development of drugs and high-tech medical devices in Europe and in the USA. After she earned a medical degree from the University of Toulouse in France, she obtained inter-university degrees in methodology for clinical development, pharmacovigilance, and pharmaco-epidemiology. In 2004, she joined the Stragen Group for the clinical development of orphan drugs as well as for project coordination with the European Medicines Agency. She is now managing a sister company within the Stragen Group, dedicated to services in clinical development strategy and pharmacovigilance. She has the CMO position in Alaxia’s orphan drug project for the treatment of cystic fibrosis.

Appearing:

World Orphan Drug Congress Day 2 Wednesday 30th November 2011

10am

Panel discussion: Engaging in an open dialogue throughout the clinical trial stage

Unprecedented clinical trials require established validity of primary endpoints
When and how should all stakeholders communicate during orphan drug development?
How can market approval be optimised during the clinical stages?
Where has open dialogue bred success and where have talks broken down?

Annie-Claude Benichou,

CMO,
Alaxia

Thomas Meier,

CSO,
Santhera Pharmaceuticals

Alastair Kent,

Director,
Genetic Alliance UK

An Van Es-Johansson,

Head of Clinical Development,
Swedish Orphan Biovitrum

Sponsor World Orphan Drug Congress 2011 ›

Associate Sponsor